Dr. Pablo M. Tebas, MD
Infectious Disease (Infectious Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 41
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 66
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
PA license MD421328
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hospital of Univ of Pennsylvania Philadelphia, PA
- Pennsylvania Hospital Philadelphia, PA
Medical groups
- University of Penn - Medical Group (3,505 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 66
- Services billed
- 192
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 48 | 27 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 31 | 12 |
| Established patient office or other outpatient visit, 40-54 minutes | 18 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Biktarvy (bictegrav/emtricit/tenofov ala) | 84 |
| Tivicay (dolutegravir sodium) | 78 |
| Descovy (emtricitabine/tenofov alafenam) | 48 |
| Odefsey (emtricitab/rilpiviri/tenof ala) | 39 |
| Darunavir | 28 |
| Arikayce (amikacin liposomal/neb.accessr) | 27 |
| Emtricitabine-Tenofovir Disop (emtricitabine/tenofovir (tdf)) | 26 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Philadelphia, PA | 26 |
| Triumeq (abacavir/dolutegravir/lamivudi) | 25 |
| Ethambutol Hcl | 24 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 6 payments worth $12,377 in total to this clinician.
| Viiv Healthcare Company | $7,957 |
|---|---|
| Shionogi Inc | $4,420 |
| Consulting Fee | $12,220 |
|---|---|
| Food and Beverage | $157 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Viiv Healthcare Company Aug 4, 2025 | Consulting Fee | $3,900 |
| Viiv Healthcare Company Jul 23, 2025 | Consulting Fee | $3,900 |
| Shionogi Inc May 23, 2025 | Consulting Fee Fetroja · Infections and Infectious Diseases | $2,530 |
| Shionogi Inc May 23, 2025 | Consulting Fee Fetroja · Infections and Infectious Diseases | $1,890 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $659,932 in research payments for these studies, mostly to the institutions running them.
- BNT163-01
BioNTech SE - A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.